214 related articles for article (PubMed ID: 35104622)
1. An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition.
Hu L; Zhao C; Chen Z; Hu G; Li X; Li Q
Drug Discov Today; 2022 May; 27(5):1457-1463. PubMed ID: 35104622
[TBL] [Abstract][Full Text] [Related]
2. Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension.
Auth R; Klinger JR
Expert Opin Investig Drugs; 2023; 32(11):1025-1042. PubMed ID: 37881882
[TBL] [Abstract][Full Text] [Related]
3. Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension.
Martin de Miguel I; Cruz-Utrilla A; Oliver E; Escribano-Subias P
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835558
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension.
Zeng C; Liu J; Zheng X; Hu X; He Y
Respir Res; 2023 Nov; 24(1):263. PubMed ID: 37915044
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Novel Pyrazolo[3,4-
Hu L; Li L; Chang Q; Fu S; Qin J; Chen Z; Li X; Liu Q; Hu G; Li Q
J Med Chem; 2020 Oct; 63(19):11215-11234. PubMed ID: 32914624
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of natural flavonoids in pulmonary arterial hypertension: A review.
Zhang JJ; Mao-Mao ; Shao MM; Wang MC
Phytomedicine; 2024 Jun; 128():155535. PubMed ID: 38537442
[TBL] [Abstract][Full Text] [Related]
7. Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension.
Li MX; Jiang DQ; Wang Y; Chen QZ; Ma YJ; Yu SS; Wang Y
J Cardiovasc Pharmacol; 2016 Feb; 67(2):182-90. PubMed ID: 26448276
[TBL] [Abstract][Full Text] [Related]
8. Promising therapeutic approaches in pulmonary arterial hypertension.
Ali MK; Ichimura K; Spiekerkoetter E
Curr Opin Pharmacol; 2021 Aug; 59():127-139. PubMed ID: 34217109
[TBL] [Abstract][Full Text] [Related]
9. Dual-Functional MN-08 Attenuated Pulmonary Arterial Hypertension Through Vasodilation and Inhibition of Pulmonary Arterial Remodeling.
Luo F; Wu L; Xie G; Gao F; Zhang Z; Chen G; Liu Z; Zha L; Zhang G; Sun Y; Zhang Z; Wang Y
Hypertension; 2021 May; 77(5):1787-1798. PubMed ID: 33775126
[TBL] [Abstract][Full Text] [Related]
10. Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective.
Wang RR; Yuan TY; Wang JM; Chen YC; Zhao JL; Li MT; Fang LH; Du GH
Pharmacol Res; 2022 Jun; 180():106238. PubMed ID: 35504356
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances.
Mercurio V; Cuomo A; Naranjo M; Hassoun PM
Compr Physiol; 2021 Apr; 11(2):1805-1829. PubMed ID: 33792903
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Novel Hybridization from Isosorbide 5-Mononitrate and Bardoxolone Methyl with Dual Activities of Pulmonary Vasodilation and Vascular Remodeling Inhibition on Pulmonary Arterial Hypertension Rats.
Cheng Y; Gong Y; Qian S; Mou Y; Li H; Chen X; Kong H; Xie W; Wang H; Zhang Y; Huang Z
J Med Chem; 2018 Feb; 61(4):1474-1482. PubMed ID: 29377691
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs and their regulators: Potential therapeutic targets in pulmonary arterial hypertension.
He YZ; Wang YX; Ma JS; Li RN; Wang J; Lian TY; Zhou YP; Yang HP; Sun K; Jing ZC
Vascul Pharmacol; 2023 Dec; 153():107216. PubMed ID: 37699495
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets.
Bourgeois A; Omura J; Habbout K; Bonnet S; Boucherat O
Int J Biochem Cell Biol; 2018 Nov; 104():9-13. PubMed ID: 30189252
[TBL] [Abstract][Full Text] [Related]
15. CD39 in the development and progression of pulmonary arterial hypertension.
Willcox A; Lee NT; Nandurkar HH; Sashindranath M
Purinergic Signal; 2022 Dec; 18(4):409-419. PubMed ID: 35947229
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension.
Luo T; Wu H; Zhu W; Zhang L; Huang Y; Yang X
Respir Med; 2024 Jun; 227():107631. PubMed ID: 38631526
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Inheritance Underlying Pulmonary Arterial Hypertension.
Napoli C; Benincasa G; Loscalzo J
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):653-664. PubMed ID: 30727752
[TBL] [Abstract][Full Text] [Related]
18. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication.
Guignabert C; Tu L; Girerd B; Ricard N; Huertas A; Montani D; Humbert M
Chest; 2015 Feb; 147(2):529-537. PubMed ID: 25644906
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pulmonary arterial hypertension: recent progress and a look to the future.
Humbert M; Sitbon O; Guignabert C; Savale L; Boucly A; Gallant-Dewavrin M; McLaughlin V; Hoeper MM; Weatherald J
Lancet Respir Med; 2023 Sep; 11(9):804-819. PubMed ID: 37591298
[TBL] [Abstract][Full Text] [Related]
20. Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs.
Jin Q; Chen D; Zhang X; Zhang F; Zhong D; Lin D; Guan L; Pan W; Zhou D; Ge J
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
